Pharmaceutical company Dr Reddy's Laboratories today said that its consolidated net profit declined by 14.28 per cent to Rs 209.55 crore for the first quarter ended June 30, over the same period in the previous fiscal.
Net income from sales and services stood at Rs 1,683.13 crore, compared to Rs 1,818.94 crore in the same period of the corresponding fiscal, Dr Reddy's said in a filing to the Bombay Stock Exchange (BSE).
During the quarter, the company launched 32 new products and filed 25 new product registrations, it added.
The company, during the quarter, also transferred dossiers and trademarks for nine currently marketed products in Brazil to GSK, for a consideration of $4 million.
Shares of Dr Reddy's Laboratories today closed at Rs 1,380.60 on the BSE, down 1.69 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app